P
US11633377B2ActiveUtilityPatentIndex 73

Treatment of circadian rhythm disorders

Assignee: VANDA PHARMACEUTICALS INCPriority: Jan 26, 2012Filed: Feb 8, 2021Granted: Apr 25, 2023
Est. expiryJan 26, 2032(~5.6 yrs left)· nominal 20-yr term from priority
Inventors:DRESSMAN MARLENE MICHELLELICAMELE LOUIS WILLIAMPOLYMEROPOULOS MIHAEL H
A61K 9/0053A61P 25/20G01N 2800/2864A61P 25/00A61K 31/343G01N 30/7233A61K 31/15A61K 45/06A61P 25/26A61P 5/38A61P 5/00A61K 31/277G16H 50/20G01N 33/6893Y02A90/10A61K 31/496A61K 9/006A61K 31/00A61P 43/00A61P 27/00G01N 33/74A61K 2300/00A61K 31/05
73
PatentIndex Score
1
Cited by
559
References
11
Claims

Abstract

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. In a method of administering tasimelteon to an individual, the improvement comprising:
 selecting for such administration an individual having a cortisol circadian rhythm that is not entrained to the individual's day/night cycle. 
 
     
     
       2. The improvement of  claim 1 , wherein administering tasimelteon includes administering between about 10 mg and about 100 mg of tasimelteon. 
     
     
       3. The improvement of  claim 1 , wherein administering tasimelteon includes administering between about 20 mg and about 50 mg of tasimelteon. 
     
     
       4. The improvement of  claim 1 , wherein administering includes administering 20 mg of tasimelteon. 
     
     
       5. The improvement of  claim 1 , wherein administering includes administering 20 mg of tasimelteon once daily before the individual's bedtime. 
     
     
       6. The improvement of  claim 5 , wherein administering includes administering the 20 mg of tasimelteon 0.5 hour to 1.5 hour before the individual's bedtime. 
     
     
       7. The improvement of  claim 5 , wherein administering includes administering the 20 mg of tasimelteon one hour before the individual's bedtime. 
     
     
       8. The improvement of  claim 1 , wherein the individual is light perception impaired (LPI). 
     
     
       9. The improvement of  claim 1 , wherein the individual is totally blind. 
     
     
       10. The improvement of  claim 1 , wherein the individual suffers from Non-24-Hour Sleep-Wake Disorder. 
     
     
       11. The improvement of  claim 1 , further comprising:
 selecting for such administration an individual having a melatonin circadian rhythm that is not entrained to the individual's day/night cycle.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.